Skip to content

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$2.28B+84.0%
AbbVie logo
AbbVieABBV
$460.96B+24.7%
Immunome logo
ImmunomeIMNM
$1.9B+470%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$2.62B+275%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$6.02B+951%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Cash flow

See full
Operating cash flow-$8.8M+2.5%

Valuation

See full
Market cap$1.78B+674%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Calculated from SELLAS Life Sciences Group, Inc.’s reported figures.

The official record: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SELLAS Life Sciences Group, Inc.'s enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SELLAS Life Sciences Group, Inc.'s enterprise value?
SELLAS Life Sciences Group, Inc. (SLS) reported enterprise value of $653.41M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s enterprise value changed year-over-year?
SELLAS Life Sciences Group, Inc.'s enterprise value increased by 825.7% year-over-year, from $70.59M to $653.41M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s enterprise value?
Over 5 years (2020 to 2025), SELLAS Life Sciences Group, Inc.'s enterprise value has grown at a 51.7% compound annual growth rate (CAGR), from $57.98M to $466.22M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.